{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T01:50:17Z","timestamp":1781574617717,"version":"3.54.5"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01-AI069918"],"award-info":[{"award-number":["U01-AI069918"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-AI050410"],"award-info":[{"award-number":["P30-AI050410"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1-TR002489"],"award-info":[{"award-number":["UL1-TR002489"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U24-AA020794"],"award-info":[{"award-number":["U24-AA020794"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01-AA020790"],"award-info":[{"award-number":["U01-AA020790"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U24-AA022001"],"award-info":[{"award-number":["U24-AA022001"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10-AA013566"],"award-info":[{"award-number":["U10-AA013566"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>People with human immunodeficiency virus (HIV) (PWH) may be at increased risk for severe coronavirus disease 2019 (COVID-19) outcomes. We examined HIV status and COVID-19 severity, and whether tenofovir, used by PWH for HIV treatment and people without HIV (PWoH) for HIV prevention, was associated with protection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Within 6 cohorts of PWH and PWoH in the United States, we compared the 90-day risk of any hospitalization, COVID-19 hospitalization, and mechanical ventilation or death by HIV status and by prior exposure to tenofovir, among those with severe acute respiratory syndrome coronavirus 2 infection between 1 March and 30 November 2020. Adjusted risk ratios (aRRs) were estimated by targeted maximum likelihood estimation, with adjustment for demographics, cohort, smoking, body mass index, Charlson comorbidity index, calendar period of first infection, and CD4 cell counts and HIV RNA levels (in PWH only).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among PWH (n = 1785), 15% were hospitalized for COVID-19 and 5% received mechanical ventilation or died, compared with 6% and 2%, respectively, for PWoH (n = 189 351). Outcome prevalence was lower for PWH and PWoH with prior tenofovir use. In adjusted analyses, PWH were at increased risk compared with PWoH for any hospitalization (aRR, 1.31 [95% confidence interval, 1.20\u20131.44]), COVID-19 hospitalizations (1.29 [1.15\u20131.45]), and mechanical ventilation or death (1.51 [1.19\u20131.92]). Prior tenofovir use was associated with reduced hospitalizations among PWH (aRR, 0.85 [95% confidence interval, .73\u2013.99]) and PWoH (0.71 [.62\u2013.81]).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Before COVID-19 vaccine availability, PWH were at greater risk for severe outcomes than PWoH. Tenofovir was associated with a significant reduction in clinical events for both PWH and PWoH.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciad084","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T13:19:32Z","timestamp":1677763172000},"page":"1727-1734","source":"Crossref","is-referenced-by-count":17,"title":["Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6194-699X","authenticated-orcid":false,"given":"Alexandra N","family":"Lea","sequence":"first","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Oakland, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy A","family":"Leyden","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Oakland, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Sofrygin","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Oakland, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben J","family":"Marafino","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Oakland, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Skarbinski","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Oakland, California , USA"},{"name":"Oakland Medical Center, Kaiser Permanente Northern California , Oakland, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Napravnik","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deana","family":"Agil","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Augenbraun","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, State University of New York Health Sciences University , Brooklyn , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorie","family":"Benning","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Horberg","sequence":"additional","affiliation":[{"name":"Mid-Atlantic Permanente Research Institute, Kaiser Permanente Mid-Atlantic States , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeena","family":"Jefferson","sequence":"additional","affiliation":[{"name":"Mid-Atlantic Permanente Research Institute, Kaiser Permanente Mid-Atlantic States , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent C","family":"Marconi","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine and Rollins School of Public Health, Atlanta Veterans Affairs Medical Center , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3848-7753","authenticated-orcid":false,"given":"Lesley S","family":"Park","sequence":"additional","affiliation":[{"name":"Stanford Department of Epidemiology & Population Health, Stanford University School of Medicine , Palo Alto, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsha S","family":"Gordon","sequence":"additional","affiliation":[{"name":"VA Connecticut Healthcare System , West Haven, Connecticut , USA"},{"name":"Department of Internal Medicine, Yale School of Medicine , New Haven, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bastarache","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Vanderbilt University Medical Center , Nashville, Tennessee , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srushti","family":"Gangireddy","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Vanderbilt University Medical Center , Nashville, Tennessee , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5068-6595","authenticated-orcid":false,"given":"Keri N","family":"Althoff","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6423-1137","authenticated-orcid":false,"given":"Sally B","family":"Coburn","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly A","family":"Gebo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raynell","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Calgary , Calgary, Alberta , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Williams","sequence":"additional","affiliation":[{"name":"Epidemiology Branch, Division of AIDS, National Institute of Allergy and Infectious Diseases , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9322-1395","authenticated-orcid":false,"given":"Michael J","family":"Silverberg","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Oakland, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"key":"2023053103402401200_ciad084-B1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/QAI.0000000000002578","article-title":"Clinical outcomes and inflammatory markers by HIV serostatus and viral suppression in a large cohort of patients hospitalized with COVID-19","volume":"86","author":"Patel","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023053103402401200_ciad084-B2","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/cid\/ciaa880","article-title":"Coronavirus 2019 and people living with human immunodeficiency virus: outcomes for hospitalized patients in New York City","volume":"71","author":"Sigel","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023053103402401200_ciad084-B3","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1016\/S2352-3018(20)30164-8","article-title":"Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort","volume":"7","author":"Vizcarra","year":"2020","journal-title":"Lancet HIV"},{"key":"2023053103402401200_ciad084-B4","article-title":"COVID-19 in the largest US HIV cohort","author":"Park","year":"2020"},{"key":"2023053103402401200_ciad084-B5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.37069","article-title":"COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State","volume":"4","author":"Tesoriero","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2023053103402401200_ciad084-B6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.36397","article-title":"Analysis of severe illness after postvaccination COVID-19 breakthrough among adults with and without HIV in the US","volume":"5","author":"Lang","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2023053103402401200_ciad084-B7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/QAD.0000000000003393","article-title":"Outcomes following severe acute respiratory syndrome coronavirus 2 infection among individuals living with and without HIV in Denmark","volume":"37","author":"Rasmussen","year":"2023","journal-title":"AIDS"},{"key":"2023053103402401200_ciad084-B8","article-title":"COVID-19 disease severity among people with HIV infection or solid organ transplant in the United States: a nationally-representative, multicenter, observational cohort study","author":"Sun","journal-title":"medRxiv"},{"key":"2023053103402401200_ciad084-B9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jinf.2021.05.020","article-title":"Comparison of outcomes in HIV-positive and HIV-negative patients with COVID-19","volume":"83","author":"Venturas","year":"2021","journal-title":"J Infect"},{"key":"2023053103402401200_ciad084-B10","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026573","article-title":"HIV Infection and risk of COVID-19 mortality: a meta-analysis","volume":"100","author":"Dong","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2023053103402401200_ciad084-B11","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.4102\/sajhivmed.v22i1.1220","article-title":"Human immunodeficiency virus and mortality from coronavirus disease 2019: a systematic review and meta-analysis","volume":"22","author":"Hariyanto","year":"2021","journal-title":"South Afr J HIV Med"},{"key":"2023053103402401200_ciad084-B12","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1038\/s41598-021-85359-3","article-title":"Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis","volume":"11","author":"Ssentongo","year":"2021","journal-title":"Sci Rep"},{"key":"2023053103402401200_ciad084-B13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11904-022-00618-w","article-title":"COVID-19 outcomes and risk factors among people living with HIV","volume":"19","author":"Spinelli","year":"2022","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2023053103402401200_ciad084-B14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258154","article-title":"Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: a population-based cohort study","volume":"16","author":"Ge","year":"2021","journal-title":"PLoS One"},{"key":"2023053103402401200_ciad084-B15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003321","article-title":"Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: a federated electronic medical record analysis","volume":"17","author":"Harrison","year":"2020","journal-title":"PLoS Med"},{"key":"2023053103402401200_ciad084-B16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/QAI.0000000000002989","article-title":"Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March\u2013December 2020","volume":"90","author":"Shapiro","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023053103402401200_ciad084-B17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12879-022-07068-0","article-title":"Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials","volume":"22","author":"Vegivinti","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2023053103402401200_ciad084-B18","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/QAD.0000000000003314","article-title":"Tenofovir disoproxil fumarate and COVID-19 outcomes in men with HIV","volume":"36","author":"Li","year":"2022","journal-title":"AIDS"},{"key":"2023053103402401200_ciad084-B19","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa455","article-title":"Preventive efficacy of tenofovir\/emtricitabine against severe acute respiratory syndrome coronavirus 2 among pre-exposure prophylaxis users","volume":"7","author":"Ayerdi","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023053103402401200_ciad084-B20","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac188","article-title":"Severe acute respiratory syndrome coronavirus 2 seroprevalence among HIV-negative participants using tenofovir\/emtricitabine-based preexposure prophylaxis in 2020: a substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero cohorts","volume":"9","author":"Delaugerre","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023053103402401200_ciad084-B21","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1097\/EDE.0000000000001235","article-title":"Antiretrovirals and risk of COVID-19 diagnosis and hospitalization in HIV-positive persons","volume":"31","author":"Del Amo","year":"2020","journal-title":"Epidemiology"},{"key":"2023053103402401200_ciad084-B22","doi-asserted-by":"crossref","first-page":"536","DOI":"10.7326\/M20-3689","article-title":"Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study","volume":"173","author":"Del Amo","year":"2020","journal-title":"Ann Intern Med"},{"key":"2023053103402401200_ciad084-B23","doi-asserted-by":"crossref","first-page":"e2005","DOI":"10.1093\/cid\/ciaa1198","article-title":"Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the Western Cape Province, South Africa","volume":"73","author":"Boulle","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023053103402401200_ciad084-B24","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/QAI.0000000000002896","article-title":"Incidence and severity of SARS-CoV-2 infection in HIV-infected individuals during the first year of the pandemic","volume":"89","author":"Rial-Crestelo","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023053103402401200_ciad084-B25","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1097\/QAD.0000000000003372","article-title":"Tenofovir disoproxil fumarate\/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection","volume":"36","author":"Del Amo","year":"2022","journal-title":"AIDS"},{"key":"2023053103402401200_ciad084-B26","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101242","article-title":"Effectiveness of rosuvastatin plus colchicine, emtricitabine\/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial","volume":"43","author":"Gait\u00e1n-Duarte","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2023053103402401200_ciad084-B27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmi.2022.07.006","article-title":"Daily tenofovir disoproxil fumarate\/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers","volume":"29","author":"Polo","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2023053103402401200_ciad084-B28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/QAI.0000000000002943","article-title":"SARS-CoV-2 testing and positivity among persons with and without HIV in 6 United States cohorts","volume":"90","author":"Park","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023053103402401200_ciad084-B29","doi-asserted-by":"crossref","first-page":"F3","DOI":"10.1097\/QAD.0000000000002666","article-title":"Characteristics and outcomes of COVID-19 in patients with HIV: a multicentre research network study","volume":"34","author":"Hadi","year":"2020","journal-title":"AIDS"},{"key":"2023053103402401200_ciad084-B30","doi-asserted-by":"crossref","first-page":"458","DOI":"10.7555\/JBR.34.20200044","article-title":"Identification of therapeutic drugs against COVID-19 through computational investigation on drug repurposing and structural modification","volume":"34","author":"Yun","year":"2020","journal-title":"J Biomed Res"},{"key":"2023053103402401200_ciad084-B31","doi-asserted-by":"crossref","DOI":"10.1016\/j.imu.2021.100531","article-title":"Identification of potential antivirals against SARS-CoV-2 using virtual screening method","volume":"23","author":"Rahman","year":"2021","journal-title":"Inform Med Unlocked"},{"key":"2023053103402401200_ciad084-B32","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117652","article-title":"In silico studies on therapeutic agents for COVID-19: drug repurposing approach","volume":"252","author":"Shah","year":"2020","journal-title":"Life Sci"},{"key":"2023053103402401200_ciad084-B33","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3390\/ph14050454","article-title":"Tenofovir, another inexpensive, well-known and widely available old drug repurposed for SARS-COV-2 infection","volume":"14","author":"Zanella","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2023053103402401200_ciad084-B34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173720","article-title":"Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19","volume":"890","author":"Toor","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"2023053103402401200_ciad084-B35","first-page":"1552","article-title":"Tenofovir disoproxil fumarate: new chemical developments and encouraging in vitro biological results for SARS-CoV-2","volume":"31","author":"Closoki","year":"2020","journal-title":"J Braz Chem Soc"},{"key":"2023053103402401200_ciad084-B36","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01114-20","article-title":"Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets","volume":"11","author":"Park","year":"2020","journal-title":"mBio"},{"key":"2023053103402401200_ciad084-B37","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100993","article-title":"Effect of tenofovir disoproxil fumarate and emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: a pilot, randomized, open-label phase 2 trial","volume":"38","author":"Parienti","year":"2021","journal-title":"EClinicalMedicine"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad084\/49399684\/ciad084.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/10\/1727\/50490865\/ciad084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/10\/1727\/50490865\/ciad084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T05:17:34Z","timestamp":1685510254000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/10\/1727\/7067275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,3,2]]},"published-print":{"date-parts":[[2023,5,24]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad084","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,15]]},"published":{"date-parts":[[2023,3,2]]}}}